US.INCY · Incyte

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.670571245186136,
        "turnoverUsdM": 190.17845408000002,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.INCY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 117.9828,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 5.3,
      "take_profit_price": 131.7022,
      "target_multiplier": 1.9,
      "technical_strength": 1.68,
      "take_profit_percent": 5.7
    },
    "positionPoints": 1.4,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.341142490372272,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 63.2,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 58.2,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 5
  },
  "market": {
    "ma20": 125.2515,
    "ma50": 122.9126,
    "close": 124.64,
    "prevClose": 126.93,
    "avgVolume20": 1454804,
    "volumeRatio": 1.05,
    "changePercent": -1.8
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 5,
    "details": {
      "ret_5d": -0.000881763527054158,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 5,
      "vcp_bonus": 0,
      "vol_ratio": 1.0620931285904207,
      "ret_points": 0,
      "vol_points": 2,
      "range_ratio": 1.3859513623676583,
      "volat_points": 2,
      "day_range_pct": 0.03433889602053905,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 63.2,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 100,
        "contribution": 5
      },
      {
        "raw": 8.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 42,
        "contribution": 8.4
      },
      {
        "raw": 11.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 78.67,
        "contribution": 11.8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 66,
        "contribution": 6.6
      },
      {
        "raw": 20.4,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 68,
        "contribution": 20.4
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 58.2,
    "details": [
      "基本面分析總分: 5/5分",
      "資金流分析總分: 8.4/20分",
      "市場環境分析總分: 11.8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.6/10分",
      "技術信號分析總分: 20.4/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 5,
      "資金流": 8.4,
      "市場環境": 11.8,
      "情緒分析": 4,
      "技術信號": 20.4,
      "風險管理": 6.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.5,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 190.17845408000002,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.INCY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "良好",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 14.21
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 718.2184960000001,
                "ma50": 711.4151976999997,
                "name": "QQQ",
                "close": 741.21002,
                "points": 2
              },
              "spy": {
                "ma20": 765.28299795,
                "ma50": 760.9057979799998,
                "name": "SPY",
                "close": 767.81,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.670571245186136,
          "atrPoints": 3,
          "cciPoints": 2.4,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142310717,
                "url": "https://finnhub.io/api/news?id=2094a2c5f9c153b52aeda12f343c88808922fee79702e16bb8ec9cad1deb9cd3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.",
                "category": "company",
                "datetime": 1789988803,
                "headline": "FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week"
              },
              {
                "id": 142251199,
                "url": "https://finnhub.io/api/news?id=a581129efd1456cf0c04bbcd52a533fb0e0cec3f6e1787c33892f5e1d2478b14",
                "image": "https://www.chartmill.com/images/uploads/minervini_news_8825971f4b.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCY combines Minervini Trend Template strength, 93.53 RS, and high-growth momentum. Technical Rating 9, but watch resistance near 129.93 for breakout.",
                "category": "company",
                "datetime": 1789729273,
                "headline": "Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum"
              },
              {
                "id": 142233645,
                "url": "https://finnhub.io/api/news?id=628cdb077efa7dcbb14e295748e75d17a126177cf8c1528d4947d8259144ebe3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Mirum and Incyte are now awaiting the FDA’s decision on zilurgisertib, a once-a-day pill for an ultra-rare bone disease.",
                "category": "company",
                "datetime": 1789685045,
                "headline": "MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains?"
              },
              {
                "id": 142209442,
                "url": "https://finnhub.io/api/news?id=01434c6061042e370d190aeae26cbdd1dde460e5cefb2c5a281fbc29d5982136",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) drew fresh attention after Ontario agreed to fund MINJUVI for relapsed or refractory follicular lymphoma through its FAST Program, giving eligible patients earlier access while reimbursement reviews continue. For context, Incyte’s share price has climbed 27.0% over the past 90 days and the year-to-date share price return is 23.0%. Meanwhile, the 1-year total shareholder return of 47.1% and 3-year total shareholder return of 106.6% point to momentum that long-term holders have...",
                "category": "company",
                "datetime": 1789611102,
                "headline": "Is Incyte (INCY) Undervalued After Ontario Backed MINJUVI Access?"
              },
              {
                "id": 142199262,
                "url": "https://finnhub.io/api/news?id=9f06b7c48f31066b68bce141e7de420b582718f18e7b044b6cb18222e476eba6",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation (INCY) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 12:20 PM EDTCompany ParticipantsWilliam Meury - CEO...",
                "category": "company",
                "datetime": 1789574498,
                "headline": "Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              },
              {
                "id": 142141690,
                "url": "https://finnhub.io/api/news?id=c44673cb5a423d969d900d2c2765f99b2937982c87182f53afa88f1de7cd14e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.",
                "category": "company",
                "datetime": 1789412340,
                "headline": "INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?"
              },
              {
                "id": 142137414,
                "url": "https://finnhub.io/api/news?id=e371799cf3ec03c808a7cbfb480d2dde5b32d4db001663b1dc1fbeee97da379c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte’s 29% return over the past six months has outpaced the S&P 500 by 15.7%, and its stock price has climbed to $119.95 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1789390770,
                "headline": "Incyte (INCY): 3 Reasons We Love This Stock"
              },
              {
                "id": 142062386,
                "url": "https://finnhub.io/api/news?id=cbdf9e44ebf153e16bafde7455595e4489e06365be622abf30df7d147a3d3035",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation (INCY) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 9:45 AM EDTCompany ParticipantsWilliam Meury - CEO...",
                "category": "company",
                "datetime": 1789043236,
                "headline": "Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript"
              }
            ],
            "raw_source": [
              {
                "id": 142358803,
                "url": "https://finnhub.io/api/news?id=87962f9bb4b6eb0c25e3cfa1c05685a4b675d266644338f9cd62473a6e65ac29",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.",
                "category": "company",
                "datetime": 1790166480,
                "headline": "6 ‘Moonshot’ Biotech Stocks That Offer Big Risks, Bigger Rewards"
              },
              {
                "id": 142356861,
                "url": "https://finnhub.io/api/news?id=048dae12c884c5440778165c65832d70813661cfd4f68efa558a277404fa1656",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte is gaining momentum, recently outperforming the biotech sector and keeping analysts broadly positive on the stock.",
                "category": "company",
                "datetime": 1790139185,
                "headline": "How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?"
              },
              {
                "id": 142341008,
                "url": "https://finnhub.io/api/news?id=e07509feed6d582176ea1f7022d5ccea2fd1c29852470c7fb6a1daa1f4c136f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Dow Jones tech titan Amazon stock is battling with a key support level and approaching multiple new buy points.",
                "category": "company",
                "datetime": 1790098003,
                "headline": "Dow Jones Tech Titan Amazon Eyes Buy Point Amid Battle With Key Support Level"
              },
              {
                "id": 142340116,
                "url": "https://finnhub.io/api/news?id=aeed3fe8849fb6aa28c94f0efc6389f48c242be154e36226fb51b45dc7c367d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte's (INCY) colorectal cancer or CRC programs remain \"risky and more long-term,\" RBC Capital Mar",
                "category": "company",
                "datetime": 1790091909,
                "headline": "Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says"
              },
              {
                "id": 142337151,
                "url": "https://finnhub.io/api/news?id=ec15db9f3538528033e3a2b785c80a05463d3015aa798d3d099f3d82dfb34f1d",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "Get insights into the top gainers and losers in the S&P500 index of Tuesday's pre-market session.",
                "category": "company",
                "datetime": 1790080501,
                "headline": "Discover the top S&P500 movers in Tuesday's pre-market session."
              },
              {
                "id": 142338131,
                "url": "https://finnhub.io/api/news?id=29b6ec4222978b9a1e65396ac18d0b1804ad3eb89b0343b51086c32382719d8f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., September 22, 2026--Incyte Data at the 2026 EADV Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio",
                "category": "company",
                "datetime": 1790080200,
                "headline": "Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio"
              },
              {
                "id": 142339322,
                "url": "https://finnhub.io/api/news?id=5e344a9f1bd46602f68ceaf49af71aeba9068605f9fd8987d1e69965ab956e21",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "RBC Capital  analyst Brian Abrahams   reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $109 price target.",
                "category": "company",
                "datetime": 1790069064,
                "headline": "RBC Capital Reiterates Sector Perform on Incyte, Maintains $109 Price Target"
              },
              {
                "id": 142339323,
                "url": "https://finnhub.io/api/news?id=59f827cac6ca47941028081fa6c55528b3d2815a1bbfe015fa3e3a79400bc8f5",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Oral PresentationsAtopic DermatitisAtopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL)(Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October",
                "category": "company",
                "datetime": 1790066161,
                "headline": "Incyte To Present Data From Its Inflammation And Autoimmunity Portfolio At The European Academy Of Dermatology And Venereology Conference, September 30-October 3"
              },
              {
                "id": 142338042,
                "url": "https://finnhub.io/api/news?id=5fbe59656eb7c8e519203883d87a9ba7e725d627ad9c93744d9bd2b9cb6b416c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/22/Stockholm--Sweden---October-8--2021-An-O.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.",
                "category": "company",
                "datetime": 1790064067,
                "headline": "Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session"
              },
              {
                "id": 142310717,
                "url": "https://finnhub.io/api/news?id=2094a2c5f9c153b52aeda12f343c88808922fee79702e16bb8ec9cad1deb9cd3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.",
                "category": "company",
                "datetime": 1789988803,
                "headline": "FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week"
              },
              {
                "id": 142291354,
                "url": "https://finnhub.io/api/news?id=1e8e127ca473ed1c75eed9faf8ea2c32eb99dfeff39a2f89f8005a159838fe5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: INCY), to commercialise, distribute, and register ruxolitinib cream (registered as Opzelura® in the U.S. and European Union) in Australia.",
                "category": "company",
                "datetime": 1789934400,
                "headline": "Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia"
              },
              {
                "id": 142277352,
                "url": "https://finnhub.io/api/news?id=fa32183130775dd71561fd6fc458532c82f005b944d06280d442f2121a70a101",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029. Chief Executive Officer Bill Meury said the company’s pipeline has changed substantially over t",
                "category": "company",
                "datetime": 1789869726,
                "headline": "Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target"
              },
              {
                "id": 142270936,
                "url": "https://finnhub.io/api/news?id=64ab13c25410463853c539597d8b85ea92d766443816efe08bdfb20887bc0cba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Robinhood stock surged in an end-of-week crypto rally. SpaceX is testing an aggressive entry. They lead five stocks near buy points.",
                "category": "company",
                "datetime": 1789819239,
                "headline": "Robinhood Soars, SpaceX Orbits Entry: Five Stocks Near Buy Points"
              },
              {
                "id": 142260296,
                "url": "https://finnhub.io/api/news?id=a8f8b27d7a050cf25b8b0188ed53de38748f509bf5a2409465592db1fc826c46",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte is Friday's IBD Stock Of The Day. Shares are testing a trendline within a base. That would offer an early entry into the biotech..",
                "category": "company",
                "datetime": 1789750335,
                "headline": "IBD Stock Of The Day Eyes Buy Points As Investors Dig Into Its Pipeline"
              },
              {
                "id": 142252050,
                "url": "https://finnhub.io/api/news?id=8a29ce95b8561e45cc4eae2eca551ccca3c17ca7c92fdd223266bfff202193b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.",
                "category": "company",
                "datetime": 1789731968,
                "headline": "Dow Jones Futures: After S&P 500, Nasdaq Rebound, What's Next? Moderna, AMD, SpaceX Flash Buy Signals."
              },
              {
                "id": 142251199,
                "url": "https://finnhub.io/api/news?id=a581129efd1456cf0c04bbcd52a533fb0e0cec3f6e1787c33892f5e1d2478b14",
                "image": "https://www.chartmill.com/images/uploads/minervini_news_8825971f4b.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCY combines Minervini Trend Template strength, 93.53 RS, and high-growth momentum. Technical Rating 9, but watch resistance near 129.93 for breakout.",
                "category": "company",
                "datetime": 1789729273,
                "headline": "Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum"
              },
              {
                "id": 142250252,
                "url": "https://finnhub.io/api/news?id=34adaed45b12e382bfc23bef5a02b53d134a188f8fd2d03dc77212031e8e6135",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.",
                "category": "company",
                "datetime": 1789728962,
                "headline": "Dow Jones Futures Rise After Bullish S&P 500, Nasdaq Rebound; Moderna, AMD, SpaceX Flash Buy Signals"
              },
              {
                "id": 142236430,
                "url": "https://finnhub.io/api/news?id=1b353f221d269fb06c0864981159bf974df8dcf5f648a2490a0e7f238230c195",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.",
                "category": "company",
                "datetime": 1789700941,
                "headline": "Dow Jones Futures: S&P 500, Nasdaq Rebound Above Key Level; Moderna, AMD, SpaceX Flash Buy Signals"
              },
              {
                "id": 142232487,
                "url": "https://finnhub.io/api/news?id=bed0ef3889913874d68a6e92a2b05cc58de8c0d87d9dfc9067a9693b32aad3e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.",
                "category": "company",
                "datetime": 1789696144,
                "headline": "Dow Jones Futures Fall After S&P 500, Nasdaq Rebound Above Key Level; Moderna, AMD, SpaceX Flash Buy Signals"
              },
              {
                "id": 142233645,
                "url": "https://finnhub.io/api/news?id=628cdb077efa7dcbb14e295748e75d17a126177cf8c1528d4947d8259144ebe3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Mirum and Incyte are now awaiting the FDA’s decision on zilurgisertib, a once-a-day pill for an ultra-rare bone disease.",
                "category": "company",
                "datetime": 1789685045,
                "headline": "MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains?"
              },
              {
                "id": 142224040,
                "url": "https://finnhub.io/api/news?id=0c980ff08b24c8c18f83a9ff8e04d78ba6d1d8579182f39d9771f7189428fda3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.",
                "category": "company",
                "datetime": 1789645097,
                "headline": "3 Growth Stocks to Add to Your Roster"
              },
              {
                "id": 142225243,
                "url": "https://finnhub.io/api/news?id=d0573a7b47114c789f926d1ea0a14e1fb05e97d846ab26128a3e6da3c7cbaa88",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/17/Charles-Schwab.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "CNBC final trades: Pros picked Schwab, Cleveland-Cliffs, UnitedHealth and Incyte; shares posted mixed moves Wednesday.",
                "category": "company",
                "datetime": 1789630302,
                "headline": "Charles Schwab, UnitedHealth And Cleveland-Cliffs: CNBC’s ‘Final Trades’"
              },
              {
                "id": 142209442,
                "url": "https://finnhub.io/api/news?id=01434c6061042e370d190aeae26cbdd1dde460e5cefb2c5a281fbc29d5982136",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) drew fresh attention after Ontario agreed to fund MINJUVI for relapsed or refractory follicular lymphoma through its FAST Program, giving eligible patients earlier access while reimbursement reviews continue. For context, Incyte’s share price has climbed 27.0% over the past 90 days and the year-to-date share price return is 23.0%. Meanwhile, the 1-year total shareholder return of 47.1% and 3-year total shareholder return of 106.6% point to momentum that long-term holders have...",
                "category": "company",
                "datetime": 1789611102,
                "headline": "Is Incyte (INCY) Undervalued After Ontario Backed MINJUVI Access?"
              },
              {
                "id": 142200639,
                "url": "https://finnhub.io/api/news?id=b5d523235573dcfeba3a034b33cd96fff4bafdc2078a47f853a6a557590b0058",
                "image": "",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "",
                "category": "company",
                "datetime": 1789588010,
                "headline": "Tracking Baker Brothers' Portfolio: Q2 2026 Update"
              },
              {
                "id": 142199262,
                "url": "https://finnhub.io/api/news?id=9f06b7c48f31066b68bce141e7de420b582718f18e7b044b6cb18222e476eba6",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation (INCY) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 12:20 PM EDTCompany ParticipantsWilliam Meury - CEO...",
                "category": "company",
                "datetime": 1789574498,
                "headline": "Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              },
              {
                "id": 142225244,
                "url": "https://finnhub.io/api/news?id=70e4707785aff203ce7ee6009f9ce454f7bfb436536e44e1892ed02823842517",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/16/Tumor-Microenvironment-Concept-With-Canc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.",
                "category": "company",
                "datetime": 1789565932,
                "headline": "This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales"
              },
              {
                "id": 142197499,
                "url": "https://finnhub.io/api/news?id=a0ff66b6ef4e9b713fbe35e61a0980272fafb54317baeaf055a5718980e59b78",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2223338940/image_2223338940.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Mirum Pharmaceuticals is technically oversold but is likely to have more major drug pipeline catalysts occur in the coming months. Click for more on MIRM.",
                "category": "company",
                "datetime": 1789560721,
                "headline": "Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Events"
              },
              {
                "id": 142186094,
                "url": "https://finnhub.io/api/news?id=b45ddb830214e435f9e6259735ec1b1e3e5239ea87fe9fbff66426061d513231",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.",
                "category": "company",
                "datetime": 1789544389,
                "headline": "1 Cash-Heavy Stock for Long-Term Investors and 2 We Ignore"
              },
              {
                "id": 142159413,
                "url": "https://finnhub.io/api/news?id=9940f11e00ef11b56fbaf4dd13b897e7b572f3bdadc1b454dd5583cd521952fa",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/964042876/image_964042876.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Damora Therapeutics targets myeloproliferative neoplasms with a pipeline led by DMR-001, now in Phase 1/1b trials. Learn why DMRA stock is a hold.",
                "category": "company",
                "datetime": 1789455910,
                "headline": "Damora Therapeutics: Potential Payday Is A Long Way Off"
              },
              {
                "id": 142157694,
                "url": "https://finnhub.io/api/news?id=64c36ae0193a4e2d634bcbbe22e26f06d8c709cc31f4aab7f4b4d42d143a974b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1493093301/image_1493093301.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte (INCY) stock rated Sell: valuation assumes high pipeline success.",
                "category": "company",
                "datetime": 1789450454,
                "headline": "Incyte: Priced For Success, With No Margin Of Safety"
              },
              {
                "id": 142141690,
                "url": "https://finnhub.io/api/news?id=c44673cb5a423d969d900d2c2765f99b2937982c87182f53afa88f1de7cd14e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.",
                "category": "company",
                "datetime": 1789412340,
                "headline": "INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?"
              },
              {
                "id": 142137414,
                "url": "https://finnhub.io/api/news?id=e371799cf3ec03c808a7cbfb480d2dde5b32d4db001663b1dc1fbeee97da379c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte’s 29% return over the past six months has outpaced the S&P 500 by 15.7%, and its stock price has climbed to $119.95 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1789390770,
                "headline": "Incyte (INCY): 3 Reasons We Love This Stock"
              },
              {
                "id": 142089688,
                "url": "https://finnhub.io/api/news?id=fa78841ae516d242c118f639be92d94e46b09fe684fb41ba03a2c85b445e1854",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.",
                "category": "company",
                "datetime": 1789150745,
                "headline": "2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off"
              },
              {
                "id": 142085128,
                "url": "https://finnhub.io/api/news?id=95741dde0efa5cad7e611da0864eb37e06641281f8b6e3f001bd71bda1dfc861",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte stock is trading just below a buy zone just as Big Money is giving it the stamp of approval.  Shares popped in July following a strong earnings report that impressed investors.  Incyte stock shows an ideal Composite Rating of 99, boosted by steady year-over-year earnings growth and a decent Relative Strength Rating of 88.",
                "category": "company",
                "datetime": 1789128027,
                "headline": "Profitable Biotech Incyte Forms Handle As Institutional Buyers Load Up On Stock"
              },
              {
                "id": 142115363,
                "url": "https://finnhub.io/api/news?id=759f2770fa321269e8d716d23926c2d80024c876f54cf0000fc45317d7152dcd",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.25% on an annualized basis producing an average annual return of 17.44%. Currently, Incyte has a market capitalization of $24.69 billion.",
                "category": "company",
                "datetime": 1789126225,
                "headline": "Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today"
              },
              {
                "id": 142066345,
                "url": "https://finnhub.io/api/news?id=0a89bb8bbdf6e29ec456040b4b7e975b5b537c5f8cb7cf64eefc87ed7086ded0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody-drug conjugate (ADC) cancer treatments, today announced the appointment of Vijay Iyengar, MD, to its Board of Directors, effective September 9, 2026.",
                "category": "company",
                "datetime": 1789070700,
                "headline": "Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors"
              },
              {
                "id": 142061002,
                "url": "https://finnhub.io/api/news?id=54538e33e8ab33e76186cce9f3759cc966cc32ebf2e0e61c1c61290c43869c3b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NYSE: INCY) today announced that MINJUVI® (tafasitamab) in the treatment of relapsed or refractory follicular lymphoma (R/R FL) has been funded in the province of Ontario through Ontario's Funding Accelerated for Specific Treatments (FAST) Program. Through this program, eligible patients may gain access to treatment sooner while formal reimbursement processes continue.1,2",
                "category": "company",
                "datetime": 1789045200,
                "headline": "Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program"
              },
              {
                "id": 142062386,
                "url": "https://finnhub.io/api/news?id=cbdf9e44ebf153e16bafde7455595e4489e06365be622abf30df7d147a3d3035",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation (INCY) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 9:45 AM EDTCompany ParticipantsWilliam Meury - CEO...",
                "category": "company",
                "datetime": 1789043236,
                "headline": "Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript"
              },
              {
                "id": 142027202,
                "url": "https://finnhub.io/api/news?id=263fdaa9cbb41d995e74a0de94de6961b766a91c507cdbf54c7f612561a4aa9d",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation (INCY) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 11:00 AM EDTCompany ParticipantsWilliam Meury - CEO &...",
                "category": "company",
                "datetime": 1788961630,
                "headline": "Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 142025172,
                "url": "https://finnhub.io/api/news?id=f47919b23f1416ade31c074dd57b0bf69f46b300135f105f8490b9a26f86e126",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1314008084/image_1314008084.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "MacroGenics (MGNX) trades below cash with a strong ADC/TCE pipeline and ESMO 2026 catalysts.",
                "category": "company",
                "datetime": 1788948935,
                "headline": "MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead"
              },
              {
                "id": 141940129,
                "url": "https://finnhub.io/api/news?id=ed641022f688203b147fe7fa1471c3eecf435dbea2135f60a28ef214ccb06cff",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCYTE CORP (INCY) passes a high growth momentum + technical breakout screen, with strong earnings, ratings of 6/10 momentum, and 10/10 technical setup.",
                "category": "company",
                "datetime": 1788867083,
                "headline": "Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup"
              },
              {
                "id": 141880520,
                "url": "https://finnhub.io/api/news?id=2b454da8ecc1536e2ee48d239ede2c2c3508ade465316c12f84769f91a08e3c0",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2265725036/image_2265725036.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation outperformed, rising 34% versus the S&P 500's 15% since March 2026. Find out why INCY stock is a Hold.",
                "category": "company",
                "datetime": 1788843461,
                "headline": "Incyte: Solid Strategies For Continued Growth, But A Possible Pullback Looms"
              },
              {
                "id": 141431780,
                "url": "https://finnhub.io/api/news?id=c212dc388872a3607312857e51ed8ee7ac1abff8186288b14b59c9609958ac93",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
                "category": "company",
                "datetime": 1788529570,
                "headline": "2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off"
              },
              {
                "id": 141400653,
                "url": "https://finnhub.io/api/news?id=875032664570c6166afea11a4406f4c881d1eb853fe90b5fdde194d7d17c2561",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449405,
                "headline": "Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?"
              },
              {
                "id": 141374864,
                "url": "https://finnhub.io/api/news?id=ce10dda922ad87853921bc27993702aade129c6db2743b328af3639316380458",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2141587595/image_2141587595.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. See why INCY stock is a Buy.",
                "category": "company",
                "datetime": 1788322299,
                "headline": "Incyte Corporation: Why Jakafi Is No Longer The Real Story Here"
              },
              {
                "id": 141365208,
                "url": "https://finnhub.io/api/news?id=288414dfabfdb4bc07a96be120c7d403b8fe45a22feba07a6ce0011dd87d197d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., September 01, 2026--Incyte to Present at Upcoming Investor Conferences",
                "category": "company",
                "datetime": 1788267600,
                "headline": "Incyte to Present at Upcoming Investor Conferences"
              },
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141364578,
                "url": "https://finnhub.io/api/news?id=db1dc8bd97bef642bf3b08ebd399985594b48b71463b04394befe22f506dafbc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "In a recent interview on CNBC’s Halftime Report, Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (NASDAQ: INCY) and Biogen (NASDAQ: BIIB) as two of his “Best Stocks in the Market.” Brown said he wanted to focus on stocks that had “nothing to do” with the AI and data-center spending theme. “We wanted to […]",
                "category": "company",
                "datetime": 1788101107,
                "headline": "Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks"
              },
              {
                "id": 141365209,
                "url": "https://finnhub.io/api/news?id=5105efba531f9fb2535ce16988a36b3262b276b7c3a38db894289dcbd60503bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) is back in focus following renewed attention on upcoming ESMO data for its KRAS G12D inhibitor, known as 734, which is being studied in combination with chemotherapy for pancreatic ductal adenocarcinoma. The renewed focus on Incyte comes after a strong run in the share price, with the latest close at US$124.37 and a 90 day share price return of 30.11%. That move sits within a broader trend where the year to date share price return is 22.63%, while total shareholder return over 1...",
                "category": "company",
                "datetime": 1788098701,
                "headline": "Incyte (INCY) Just Moved, So What Is Drawing Attention Now?"
              },
              {
                "id": 141365210,
                "url": "https://finnhub.io/api/news?id=31be5bd3eb6e61204d49f6616ccf01186bbfed826a67bb4c6e8ad3477e13c0eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NasdaqGS: INCY) is drawing attention as its KRAS G12D inhibitor '734 heads into new data presentations at ESMO, focused on pancreatic ductal adenocarcinoma. The upcoming ESMO readout is expected to support ongoing Phase 3 trials of '734 in pancreatic cancer, a disease area with high unmet medical need. Interest is heightened after a competitor recently received FDA approval for a therapy targeting a similar pathway in oncology. This spotlight on Incyte shows how much investor...",
                "category": "company",
                "datetime": 1788074251,
                "headline": "Incyte (INCY) Nears New ESMO Data For KRAS G12D Candidate 734"
              },
              {
                "id": 141365211,
                "url": "https://finnhub.io/api/news?id=73624c2f9b42de813b38550908858ab02f5f27c1af4f0c82809b06fd6431226e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte Corporation (NASDAQ:INCY) generated buzz on August 19 when RBC Capital highlighted upcoming ESMO data for its KRAS G12D inhibitor ‘734 in combination with mFOLFIRINOX and GemNabP. RBC noted that while prior data was too limited for firm conclusions, the update should look “very competitive” and support ongoing Phase 3 efforts in first-line pancreatic ductal […]",
                "category": "company",
                "datetime": 1787955085,
                "headline": "Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?"
              },
              {
                "id": 141365214,
                "url": "https://finnhub.io/api/news?id=93d572f0ffe88c70f01f888a2dc3f94e6d0da03fc98ebdb7a3ab6a3707dc0c32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "uniQure (QURE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1787934629,
                "headline": "Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report?"
              },
              {
                "id": 141365215,
                "url": "https://finnhub.io/api/news?id=08b0381568f5ca924cf1bea079266efabc7196cd729013c1c4d7cce2037ac00d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (\"Knight\") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adult",
                "category": "company",
                "datetime": 1787871600,
                "headline": "Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil"
              },
              {
                "id": 141365212,
                "url": "https://finnhub.io/api/news?id=6ff59da84a8345b0319b1cf15d43eca3f37b42cd2f14386ae0cca713f1ae4aa9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1787848214,
                "headline": "Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141329710,
                "url": "https://finnhub.io/api/news?id=c13b34e21f0574f92cecc25925ba4b8bbb47870b616a052134cabcc197b77952",
                "image": "https://www.chartmill.com/images/uploads/minervini_news_8825971f4b.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCYTE (INCY) passes Minervini Trend Template & High Growth screen with strong earnings, sales, RS 93. Setup score 6/10 means wait for better entry.",
                "category": "company",
                "datetime": 1787834495,
                "headline": "Incyte (NASDAQ:INCY) Passes Minervini Trend and High-Growth Screens, But Setup Demands Patience"
              },
              {
                "id": 141322438,
                "url": "https://finnhub.io/api/news?id=5b89a111c396ce77d686a5f752a6b55a41ab4baa4c092d77332afe86e3a63eb8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192991654/image_2192991654.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million. Read why TGTX stock is upgraded to a buy.",
                "category": "company",
                "datetime": 1787731357,
                "headline": "TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)"
              },
              {
                "id": 141318466,
                "url": "https://finnhub.io/api/news?id=d7c7ff30c1b3e55ae13bdb52cc80cbe1f892ae0321e0f9170dd6c952b580763d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2282220392/image_2282220392.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Alex King from Growth Investor Pro discusses the AI cycle, semis and software.",
                "category": "company",
                "datetime": 1787679300,
                "headline": "Don't Sleep On Software"
              },
              {
                "id": 141319860,
                "url": "https://finnhub.io/api/news?id=da328127312b93726b013233096ad00c50ad124e26728165a9c7d87c98790159",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.",
                "category": "company",
                "datetime": 1787585220,
                "headline": "Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 58,
            "discarded_article_count": 43
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.4,
        "grade": "一般",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.1,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.1,
            "vcp_reason": "波幅收縮(10.6%→7%)；站上MA50；升放量(近10日3日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 1355925.2666666666,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 1663135.8,
              "avg_vol_20": 1436617.9,
              "avg_vol_30": 1355925.2666666666,
              "range_pct_10": 0.07020218228498075,
              "range_pct_20": 0.08689024390243913,
              "range_pct_30": 0.1062259306803595,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.2265689274222047,
              "dist_to_20d_high": 0.04709480122324167,
              "down_shrink_days": 1,
              "breakout_level_20d": 130.8,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6608761329305133
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.670571245186136,
              "turnoverUsdM": 190.17845408000002,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.INCY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 117.9828,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 5.3,
            "take_profit_price": 131.7022,
            "target_multiplier": 1.9,
            "technical_strength": 1.68,
            "take_profit_percent": 5.7
          },
          "positionPoints": 1.4,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.341142490372272,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 3.3286,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.67
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 11.42
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0412
    },
    "kdj": {
      "d": 54.42,
      "j": 69.67,
      "k": 59.5,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 27.06
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 3174836,
      "recentSlope": -357496.4,
      "previousSlope": -326850
    },
    "rsi": 41.68,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 120.1244,
      "position": "SAR喺價下",
      "distancePct": 3.62,
      "previousTrend": "上升"
    },
    "ma50": 122.9126,
    "macd": {
      "macd": 0.5104750437563013,
      "trend": "中性偏多",
      "signal": 0.6467678773507861,
      "histogram": -0.13629283359448485
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 125.2553,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.05,
      "score": 6,
      "avgVolume": 1454804,
      "currentVolume": 1525822
    },
    "derived": {
      "ma20": 125.2515,
      "ma50": 122.9126,
      "prevClose": 126.93,
      "avgVolume10": 1685598,
      "avgVolume20": 1454804,
      "changePercent": -1.8,
      "avgVolumeForScore": 1454804
    },
    "ma_cross": {
      "ma20": 125.2515,
      "ma50": 122.9126,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 125.5055,
      "prevMa50": 122.7174,
      "spreadPct": 1.9,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 120.9481,
      "upper": 129.5549,
      "position": "中間"
    },
    "rsi_short": 60.8,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.05
    }
  }
}

{
  "close": 124.64,
  "volume": 1525822,
  "changePercent": -1.8
}